G-protein-coupled receptors and islet function - Implications for treatment of type 2 diabetes

被引:151
作者
Winzell, Maria Sorhede [1 ]
Ahren, Bo [1 ]
机构
[1] Lund Univ, Dept Clin Sci, Div Med, Lund, Sweden
关键词
islet; insulin secretion; glucagon secretion; GPCR; type; 2; diabetes;
D O I
10.1016/j.pharmthera.2007.08.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Islet function is regulated by a number of different signals. A main signal is generated by glucose, which stimulates insulin secretion and inhibits glucagon secretion. The glucose effects are modulated by many factors, including hormones, neurotransmitters and nutrients. Several of these factors signal through guanine nucleotide-binding protein (G protein)-coupled receptors (GPCR). Examples of islet GPCR are GPR40 and GPR 119, which are GPCR with fatty acids as ligands, the receptors for the incretin hormones glucagon-like pepfide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the receptors for the islet hormones glucagon and somatostatin, the receptors for the classical neurotransmittors acetylcholine (ACh; M-3 muscarinic receptors) and noradrenaline (beta(2)- and alpha(2)-adrenoceptors) and for the neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP; PAC(1) and VPAC(2) receptors), cholecystokinin (CCKA receptors) and neuropeptide Y (NPY Y1 receptors). Other islet GPCR are the cannabinoid receptor (CB1 receptors), the vasopressin receptors (V1(B) receptors) and the purinergic receptors (P-2Y receptors). The islet GPCR couple mainly to adenylate cyclase and to phospholipase C (PLC). Since important pharmacological strategies for treatment of type 2 diabetes are stimulation of insulin secretion and inhibition of glucagon secretion, islet GPCR are potential drug targets. This review summarizes knowledge on islet GPCR. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:437 / 448
页数:12
相关论文
共 140 条
  • [1] Autonomic regulation of islet hormone secretion -: Implications for health and disease
    Ahrén, B
    [J]. DIABETOLOGIA, 2000, 43 (04) : 393 - 410
  • [2] Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes
    Ahrén, B
    Holst, JJ
    Efendic, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) : 1043 - 1048
  • [3] AHREN B, 1990, INT J PANCREATOL, V6, P1
  • [4] The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia
    Ahrén, B
    Holst, JJ
    [J]. DIABETES, 2001, 50 (05) : 1030 - 1038
  • [5] Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice
    Ahrén, B
    Sauerberg, P
    Thomsen, C
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 277 (01): : E93 - E102
  • [6] Neuropeptides and the regulation of islet function
    Ahren, Bo
    Wierup, Nils
    Sundler, Frank
    [J]. DIABETES, 2006, 55 : S98 - S107
  • [7] Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
    Ahren, Bo
    [J]. DIABETES CARE, 2007, 30 (06) : 1344 - 1350
  • [8] Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate
    Asnicar, MA
    Köster, A
    Heiman, ML
    Tinsley, F
    Smith, DP
    Galbreath, E
    Fox, N
    Ma, YL
    Blum, WF
    Hsiung, HM
    [J]. ENDOCRINOLOGY, 2002, 143 (10) : 3994 - 4006
  • [9] Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis
    Basu, R
    Chandramouli, V
    Dicke, B
    Landau, B
    Rizza, R
    [J]. DIABETES, 2005, 54 (07) : 1942 - 1948
  • [10] Activation of cannabinoid CB1 receptors induces glucose intolerance in rats
    Bermúdez-Siva, FJ
    Serrano, A
    Diaz-Molina, FJ
    Vera, IS
    Juan-Pico, P
    Nadal, A
    Fuentes, E
    de Fonseca, FR
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 531 (1-3) : 282 - 284